Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis

A. Lentnek, M. A. Sande, R. J. Whitley, G. H. McCracken, W. M. Scheld

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cryptococcus neoformans may infect persons with intact or compromised host defenses. Clinical manifestations generally correlate directly with the degree of immunosuppression. Treatment is prescribed on the basis of the severity of disease and the degree of immunosuppression. Cryptococcal meningitis is the most common clinical form of cryptococcal infection and the most amenable to study in clinical trials. The current standard of care for cryptococcal meningitis is therapy with amphotericin B. Despite clinical improvement and microbiological suppression of the organism at the completion of therapy, the microbiological outcome will be identified as presumptive persistence if treatment is continued. Patients should be observed for 1 year after completion of therapy before a final assessment is made.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume15
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Cryptococcal Meningitis
Pharmaceutical Preparations
Immunosuppression
Therapeutics
Cryptococcus neoformans
Amphotericin B
Standard of Care
Clinical Trials
Infection

ASJC Scopus subject areas

  • Immunology

Cite this

Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. / Lentnek, A.; Sande, M. A.; Whitley, R. J.; McCracken, G. H.; Scheld, W. M.

In: Clinical Infectious Diseases, Vol. 15, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

Lentnek, A. ; Sande, M. A. ; Whitley, R. J. ; McCracken, G. H. ; Scheld, W. M. / Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. In: Clinical Infectious Diseases. 1992 ; Vol. 15, No. SUPPL. 1.
@article{5328538d782e4ac5bedc73493c171765,
title = "Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis",
abstract = "Cryptococcus neoformans may infect persons with intact or compromised host defenses. Clinical manifestations generally correlate directly with the degree of immunosuppression. Treatment is prescribed on the basis of the severity of disease and the degree of immunosuppression. Cryptococcal meningitis is the most common clinical form of cryptococcal infection and the most amenable to study in clinical trials. The current standard of care for cryptococcal meningitis is therapy with amphotericin B. Despite clinical improvement and microbiological suppression of the organism at the completion of therapy, the microbiological outcome will be identified as presumptive persistence if treatment is continued. Patients should be observed for 1 year after completion of therapy before a final assessment is made.",
author = "A. Lentnek and Sande, {M. A.} and Whitley, {R. J.} and McCracken, {G. H.} and Scheld, {W. M.}",
year = "1992",
language = "English (US)",
volume = "15",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis

AU - Lentnek, A.

AU - Sande, M. A.

AU - Whitley, R. J.

AU - McCracken, G. H.

AU - Scheld, W. M.

PY - 1992

Y1 - 1992

N2 - Cryptococcus neoformans may infect persons with intact or compromised host defenses. Clinical manifestations generally correlate directly with the degree of immunosuppression. Treatment is prescribed on the basis of the severity of disease and the degree of immunosuppression. Cryptococcal meningitis is the most common clinical form of cryptococcal infection and the most amenable to study in clinical trials. The current standard of care for cryptococcal meningitis is therapy with amphotericin B. Despite clinical improvement and microbiological suppression of the organism at the completion of therapy, the microbiological outcome will be identified as presumptive persistence if treatment is continued. Patients should be observed for 1 year after completion of therapy before a final assessment is made.

AB - Cryptococcus neoformans may infect persons with intact or compromised host defenses. Clinical manifestations generally correlate directly with the degree of immunosuppression. Treatment is prescribed on the basis of the severity of disease and the degree of immunosuppression. Cryptococcal meningitis is the most common clinical form of cryptococcal infection and the most amenable to study in clinical trials. The current standard of care for cryptococcal meningitis is therapy with amphotericin B. Despite clinical improvement and microbiological suppression of the organism at the completion of therapy, the microbiological outcome will be identified as presumptive persistence if treatment is continued. Patients should be observed for 1 year after completion of therapy before a final assessment is made.

UR - http://www.scopus.com/inward/record.url?scp=0026497934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026497934&partnerID=8YFLogxK

M3 - Article

C2 - 1477229

AN - SCOPUS:0026497934

VL - 15

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -